EcoDrugPlus

Calcium Channel, Voltage-Dependent, Gamma Subunit 3b

Ensembl ID : ENSDARG00000076401
Gene Symbol: CACNG3B
6 Enzyme and pathways 5 Cross references
194 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 4a

Ensembl ID : ENSDARG00000115540
Gene Symbol: CACNG4A
5 Cross references
189 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 4b

Ensembl ID : ENSDARG00000074669
Gene Symbol: CACNG4B
9 Enzyme and pathways 5 Cross references
192 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 5a

Ensembl ID : ENSDARG00000003326
Gene Symbol: CACNG5A
4 Enzyme and pathways 5 Cross references
184 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 5b

Ensembl ID : ENSDARG00000039240
Gene Symbol: CACNG5B
5 Cross references
172 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 6a

Ensembl ID : ENSDARG00000036457
Gene Symbol: CACNG6A
5 Cross references
181 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 6b

Ensembl ID : ENSDARG00000046079
Gene Symbol: CACNG6B
4 Enzyme and pathways 5 Cross references
177 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 7a

Ensembl ID : ENSDARG00000063006
Gene Symbol: CACNG7A
4 Enzyme and pathways 5 Cross references
189 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 7b

Ensembl ID : ENSDARG00000070624
Gene Symbol: CACNG7B
5 Cross references
190 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 8a

Ensembl ID : ENSDARG00000020450
Gene Symbol: CACNG8A
6 Enzyme and pathways 5 Cross references
168 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 8b

Ensembl ID : ENSDARG00000070626
Gene Symbol: CACNG8B
5 Cross references
163 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 1

Ensembl ID : ENSDARG00000073752
Gene Symbol: CACNA2D1
6 Cross references
229 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).